Fas Ligand (FasL) and Fas (APO-1/CD95) are members of the TNFR superfamily and may trigger apoptosis. Here, we aimed to elucidate the functional role of Fas signaling in an experimental model of chronic liver disease, the hepatocyte-specific NEMO knockout (NEMO Δhepa ) mice. We generated NEMO 
Introduction
The transmembrane proteins Fas-Ligand (FasL) and Fas (Fas/ CD95/APO-1) are members of the tumor necrosis factor (TNF) and TNF receptor gene superfamilies (TNFR gene superfamily), respectively, and are expressed in numerous cell types. FasL-Fas interaction plays a crucial role in immune regulation via the ability of FasL to transmit an apoptotic signal to Fas-expressing cells 1 . Particularly, the importance of the FasL/Fas axis in pathophysiology and homeostasis has been welldocumented in the liver where these proteins are expressed in hepatocytes, cholangiocytes, activated stellate cells (HSC), and Kupffer cells (KC) 2 . Downregulation or loss of Fas expression and function is frequently found in the progression of a number of human malignancies, including colon, breast, lung, and liver carcinoma 3, 4 . Thus, the FasL-Fas pathway plays a crucial role in tumor initiation and progression. It might be a plausible therapeutic target not only for progression of liver disease, but also hepatocellular carcinoma (HCC).
HCC is the fifth most common solid cancer affecting one million people per year representing the third cause of mortality by cancer worldwide 5, 6 . Escape from the immune surveillance may play an important role in liver tumorigenesis. Alteration of the FasL/Fas system is regarded as one of the mechanisms preventing the immune system from rejecting tumor cells 7 . However, little attention has been paid to the role of the Fas/FasL interaction in vivo.
Hepatocyte-specific NEMO knockout (NEMO Δhepa ) mice are susceptible to spontaneous apoptosis, which leads to chronic hepatocyte injury and regenerative proliferation, constituting a risk factor for cancer development 8 . NEMO Δhepa livers are hypersensitive towards TRAIL stimulation 9 . Moreover, we have also shown that the death receptor TNFR1, but not TRAIL, is involved in determining progression of liver injury in NEMO
Δhepa10
.
In the present study, we examined the functional role of deficient FasL/Fas signaling on disease progression and end-stage tumorigenesis in the NEMO Δhepa model.
Materials and methods

Housing and Generation of Knockout mice
Animals were maintained in the animal facility of the University Hospital RWTH Aachen according to the German legal requirements. Hepatocyte-specific IKKγ/ NEMO mice were generated by crossing loxP site-flanked (floxed [f]) NEMO gene (NEMO f/f ) with Alfp-cre transgenic animals as described before 9 . These mice were further crossed either with Fas lpr knockout mice (purchased from The Jackson Laboratory, Bar Harbor, Maine, USA) to yield NEMO −/− were used as controls. Genotypes were confirmed via PCR specific for the respective alleles using DNA from tail biopsies. Progression of liver disease was investigated in male mice between 8-9 weeks and 52-54 weeks of age. Liver injury experiments were performed on mice between 8-9 weeks of age. Serum AST and ALT were measured by standard procedures in the Institute of Clinical Chemistry, University Hospital, RWTH Aachen.
TUNEL assay
TUNEL test was performed by standard procedures.
Quantitative real-time PCR
Total RNA was purified from liver tissue using Trizol reagent (Invitrogen, Karlsruhe, Germany). Total RNA (1 μg) was used to synthesize cDNA using SuperScript firstStand Synthesis System (Invitrogen) and was resuspended in 100 μl of H 2 O. Quantitative real-time PCR was performed using SYBR Green Reagent (Invitrogen) in 7300 real-time PCR system (Applied Biosystem, Darmstadt, Germany). GAPDH expression was used to normalize gene expression, which is represented as times versus WT basal expression. Primer sequences can be provided upon request.
Histological, immunofluorescence, and immunohistochemical analysis
Livers from mice were harvested and after fixation with 4% PFA, were embedded in paraffin for further histological evaluation. H&E and Sirius Red staining were performed on liver sections. For immunofluorescence analysis, liver cryosections of 5 μm were stained with Ki-67, CD11b (BD Biosciences, Heidelberg, Germany), and F4/80 (BioRad, Hercules, USA). Slides were fixed in 4% PFA at room temperature. Secondary antibody conjugated with Cy3 (Jackson Immunoresearch, West Grove, PA) was used to obtain red fluorescence signal. Mounting solution containing DAPI (Vector Laboratories, Burlingame, CA) was used to counterstain the nuclei of hepatocytes.
Flow cytometry analysis
Hepatocytes were stained with Annexin V-FITC (BD Biosciences). Immune cells from whole liver were isolated and stained with fluorochrome-conjugated antibodies (CD4-PE, CD8-FITC, CD45-APC-Cy7, CD11b-PE, Ly6G-FITC, and F4/80 Biotin) (BD Biosciences, Heidelberg, Germany). All samples were acquired by flow cytometry (FACS Canto II; BD Biosciences) and analyzed using the Flowjo software.
Immunoblot analysis
Isolated protein samples were probed with antibodies against RIPK1 (#5389) (Pro-Sci, Poway, CA, USA), Cleaved Caspase-3 (Asp175) (Cell Signaling Technology, Massachusetts, USA), PCNA (clone PC10) (Dianova GmbH, Hamburg, Germany), and GAPDH (MCA4739; 1:5000; AbD SeroTec, Düsseldorf, Germany). As secondary antibodies, anti-rabbit-HRP (#7074; Cell Signaling) and anti-mouse-HRP (#sc-2005; Santa Cruz) were used.
Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM). Statistical significance was determined using one-way analysis of variance (ANOVA) with Bonferroni post-hoc test. Figure 1a) , we observed that these animals develop lymphadenopathy by accumulating abnormal T cells and suffer from systemic lupus erythematosus-like autoimmune disease 12 . As expected, Fas lpr and NEMO Δhepa /Fas lpr displayed splenomegalia and presence of lymph nodes in the peritoneum (Supplementary Figure 1b-d) .
Results
Generation and characterization of the NEMO
Macroscopic appearance of NEMO Δhepa /Fas lpr livers was normal. Eight-week-old NEMO Δhepa livers are histologically characterized by lack of lobular disorganization, hepatocellular hyperplasia, hypertrophy, and severe diffuse hepatocellular anisokaryosis with marked increase in the apoptotic and mitotic rate. In turn, no neoplasia was present in the hepatic parenchyma of 8-week-old NEMO Δhepa /Fas lpr livers markedly characterized by multifocal necrosis (Fig. 1a-d) . A significant decrease in markers of liver injury at 8 weeks of age was observed in serum ALT ( (Fig. 2e) . Moreover, cleavage of Caspase-3-but not protein levels of RIPK1-was absent in NEMO Δhepa /Fas lpr livers (Fig. 2e) . Altogether, these results suggest that Fas signaling might promote apoptotic cell death in NEMO Δhepa -deficient livers.
Loss of Fas attenuates fibrogenesis in NEMO
Δhepa livers
Fas might attenuate the effect of gut-derived products on liver injury. Therefore, we next aimed to investigate if this finding might also affect liver disease progression and evaluated its relevance for liver fibrogenesis in 8-week-old animals. Interestingly, deletion of Fas attenuated liver fibrosis in NEMO Δhepa . We first measured hepatic fibre formation by Sirius red staining and quantification (Fig. 3a, b) , and determined additional well-characterized pro-fibrotic markers, such as Collagen IA1, MMP2, and TIMP1 mRNA expression (Fig. 3c, d) .
The infiltration of distinct immune cell populations directed by chemotactic cytokines is a central pathogenic feature following chronic liver injury 13 . Thus, we characterized the hepatic inflammatory cell populations using qRT-PCR and FACS analysis. Figure 3a) . However, no differences were found in TGFβ levels between mouse strains (Supplementary Figure 3b ). (Fig. 4) . H&E stainings of 1-year-old NEMO Δhepa mice showed well-differentiated trabecular and solid HCC with nodules of proliferative hepatocytes with disturbed liver (Fig. 4a-d) . Additionally, a tendency towards reduced ALT was observed in 52-weeks-old NEMO Δhepa /Fas lpr compared with NEMO Δhepa mice (Fig. 4e) Figure 6a-d) .
Histopathological examination indicated that 1-year-old NEMO
Δhepa
/Fas
lpr /TNFR1 −/− knockout mice presented no signs of neoplasia, early lymphomas, and reduced number of nodules (Table 1) . However, no differences in LW/BW ratio (Fig. 5a, b) or important changes in serum AST levels albeit significantly decreased AP levels in 52-week-old NEMO Δhepa /Fas lpr /TNFR1 −/− compared with NEMO Δhepa , and NEMO Δhepa /Fas lpr mice were observed (Fig. 5c, d) (Fig. 5e, Supplementary Figure 7) . Altogether, these data show that TNF deficiency reduces tumorigenesis in NEMO Δhepa /Fas lpr livers. In order to better characterize the TNFR1-mediated effect in NEMO Δhepa /Fas lpr , the inflammatory profile of 52-week-old livers was exhaustively investigated. The number of CD11b-positive cells was statistically significantly higher in 52-week-old NEMO Δhepa livers compared to WT animals (Fig. 6c) . Elevated F4/80 cells were also found in NEMO Δhepa livers. In contrast, a trend towards reduction of CD11b and F4/80 cells in 52-weekold NEMO Δhepa /Fas lpr livers was observed ( Fig. 6a-d) . However, no differences in cell infiltration were evident between NEMO Δhepa /Fas lpr and NEMO Δhepa /Fas lpr / TNFR1 −/− animals, suggesting that TNFR1 might be more involved in modulating tumorigenesis.
Discussion
Apart from TNFR1 and TRAILR/D5, FasL/Fas is the third death receptor of the TNF receptor superfamily that can activate caspase-8-mediated apoptosis 15 . Previously, we first showed that loss of TRAILR does not improve experimental hepatitis as others have recently confirmed 10, 16 . Next, we observed that TNFR1 deletion is beneficial for the progression of chronic liver injury in NEMO Δhepa mice 10, 14 . Moreover, we specifically showed that TNFR1 deletion in hepatocytes is protective, whereas TNFR1 inactivation in bone-marrow-derived cells might be deleterious in this experimental model of chronic liver disease. In contrast, a recent study suggested no role for TNFR1 in hepatocytes in the same model albeit showing a clear trend towards reduced transaminases and tumorigenesis 16 . Since its first description in 1989, the FasR and FasL system has become the best-characterized extracellular system triggering apoptosis 17 . Accumulating evidence highlighted the importance of FasL/Fas expression in the pathogenesis of many gastrointestinal diseases including Wilson's disease, cholestatic liver disease, alcoholic hepatitis, non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) 18, 19 . In the present study, we hypothesized that Fas mediates TNF-induced cell death in NEMO-deficient hepatocytes thus triggering the progression of chronic liver disease and end-stage HCC.
As previously described 20 . Hence, these result in the expression of a completely defective Fas antigen. Thus, our experiments overcome the underestimated effect of Fas-mediated signaling in other tissues that can directly affect the development of chronic liver disease. Concomitant to our results, Hatano et al. 25 also showed that NF-κB inhibition sensitizes hepatocytes to Fas-mediated apoptosis. Altogether, our study takes into account overall Fas signaling rather than hepatocyte-specific Fas-mediated apoptosis to explain the phenotype of NEMO Δhepa mice. The FasL/Fas system is a major mechanism of certain types of cancer cells for avoiding detection and destruction by the immune system through FasL expression 
/Fas
lpr livers, which is associated with reduced fibrosis and liver tumorigenesis.
Besides a direct cytotoxic effect on hepatocytes, the TNF/TNFR1 system might be also required for Fasmediated cell death, as demonstrated by the increased resistance of TNFR1/2 double knockout mice to Fasinduced fulminant liver injury 26 . Thus, we further assessed the role of TNFR signaling in Fas signaling. As previously described as beneficial in ethanol-mediated liver injury 27 , deletion of TNFR1 in NEMO Δhepa /Fas lpr animals reduced the tumor load of these mice, indicating that TNFR1 deficiency might modulate tumor load in HCC development. Therefore, therapeutic approaches aiming to inhibit Fas-mediated liver injury might be relevant in inhibiting inflammation-driven hepatic disease progression including growth of HCC.
